$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222030832 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$2.529M	$2.400M	$2.550M
YoY Change	5.91%	-5.87%	-59.71%
Cost Of Revenue	$986.4K	$998.3K	$1.269M
YoY Change	-14.06%	-21.33%	-71.16%
Gross Profit	$1.543M	$1.402M	$1.281M
YoY Change	24.38%	9.44%	-33.62%
Gross Profit Margin	61.0%	58.41%	50.24%
Selling, General & Admin	$1.820M	$1.809M	$2.576M
YoY Change	-9.99%	-29.77%	44.71%
% of Gross Profit	118.01%	129.03%	201.08%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.820K	$17.53K	$1.750K
YoY Change	34.29%	901.71%
% of Gross Profit	0.18%	1.25%	0.14%
Operating Expenses	$1.820M	$1.809M	$2.576M
YoY Change	-9.99%	-29.77%	43.9%
Operating Profit	-$277.8K	-$407.0K	-$1.295M
YoY Change	-64.49%	-68.56%	-1024.88%
Interest Expense	-$183.0K	$130.1K	-$5.620K
YoY Change	8958.91%	-2415.07%	-43.8%
% of Operating Profit
Other Income/Expense, Net	$825.5K	-$121.7K	-$5.622K
YoY Change		2064.91%
Pretax Income	-$1.303M	-$528.7K	-$1.302M
YoY Change	66.13%	-59.38%	-1029.82%
Income Tax
% Of Pretax Income
Net Earnings	-$925.2K	-$503.0K	-$1.302M
YoY Change	17.96%	-61.36%	-1029.82%
Net Earnings / Revenue	-36.58%	-20.96%	-51.05%
Basic Earnings Per Share		-$0.06	-$0.16
Diluted Earnings Per Share	-$0.10	-$0.06	-$159.5K
COMMON SHARES
Basic Shares Outstanding	9.319M shares	8.181M shares	8.164M shares
Diluted Shares Outstanding		551.7K shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.134M	$321.7K	$3.572M
YoY Change	-63.7%	-90.99%	-46.29%
Cash & Equivalents	$1.100M	$300.0K	$3.572M
Short-Term Investments
Other Short-Term Assets	$110.9K	$249.8K	$513.8K
YoY Change	-48.74%	-51.38%	123.37%
Inventory	$119.6K	$75.95K	$94.82K
Prepaid Expenses	$110.9K	$249.8K
Receivables	$729.0K	$850.3K	$1.009M
Other Receivables	$0.00	$875.3K	$0.00
Total Short-Term Assets	$2.093M	$2.373M	$5.189M
YoY Change	-52.15%	-54.27%	-51.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.21K	$68.04K	$303.2K
YoY Change	-33.96%	-77.56%	-34.09%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.03K	$49.03K	$21.64K
YoY Change	-18.47%	126.57%	8.2%
Total Long-Term Assets	$1.617M	$2.316M	$324.8K
YoY Change	16.16%	613.07%	-73.15%
TOTAL ASSETS
Total Short-Term Assets	$2.093M	$2.373M	$5.189M
Total Long-Term Assets	$1.617M	$2.316M	$324.8K
Total Assets	$3.710M	$4.689M	$5.514M
YoY Change	-35.66%	-14.96%	-53.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$729.2K	$744.4K	$275.2K
YoY Change	52.85%	170.48%	44.85%
Accrued Expenses	$290.0K	$312.1K	$379.6K
YoY Change	7.24%	-17.8%	11.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$166.7K	$166.7K	$0.00
YoY Change
Total Short-Term Liabilities	$2.147M	$2.061M	$654.9K
YoY Change	131.83%	214.78%	23.56%
LONG-TERM LIABILITIES
Long-Term Debt	$333.3K	$333.3K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$887.0K	$938.0K	$242.0K
YoY Change	-17.1%	287.68%	-10.39%
Total Long-Term Liabilities	$887.0K	$938.0K	$242.0K
YoY Change	-17.1%	287.68%	-51.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.147M	$2.061M	$654.9K
Total Long-Term Liabilities	$887.0K	$938.0K	$242.0K
Total Liabilities	$3.367M	$3.333M	$896.8K
YoY Change	68.7%	271.62%	-12.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.70M	-$18.80M
YoY Change	21.25%
Common Stock	$99.00	$83.00
YoY Change	20.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$763.1K	$1.399M	$4.617M
YoY Change
Total Liabilities & Shareholders Equity	$3.710M	$4.689M	$5.514M
YoY Change	-35.66%	-14.96%	-53.47%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$925.2K	-$503.0K	-$1.302M
YoY Change	17.96%	-61.36%	-1029.82%
Depreciation, Depletion And Amortization	$2.820K	$17.53K	$1.750K
YoY Change	34.29%	901.71%
Cash From Operating Activities	$1.230M	-$576.9K	-$738.1K
YoY Change	-388.26%	-21.83%	-129.76%
INVESTING ACTIVITIES
Capital Expenditures	$115.0K	-$55.73K	$0.00
YoY Change	-608.63%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$115.0K	-$55.73K	$0.00
YoY Change	408.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-303.2K	-7.860K	-210.0K
YoY Change		-96.26%	-2200.0%
NET CHANGE
Cash From Operating Activities	1.230M	-576.9K	-738.1K
Cash From Investing Activities	-115.0K	-55.73K	0.000
Cash From Financing Activities	-303.2K	-7.860K	-210.0K
Net Change In Cash	811.9K	-640.5K	-948.1K
YoY Change	-280.7%	-32.44%	-138.08%
FREE CASH FLOW
Cash From Operating Activities	$1.230M	-$576.9K	-$738.1K
Capital Expenditures	$115.0K	-$55.73K	$0.00
Free Cash Flow	$1.115M	-$521.2K	-$738.1K
YoY Change	-375.93%	-29.39%	-129.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	MEDS	Loss On Inventory Investment LossOnInventoryInvestment		usd
	MEDS	Loss On Inventory Investment LossOnInventoryInvestment		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2021Q4	us-gaap	Notes Payable NotesPayable		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q2	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions		usd
CY2022Q2	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash		usd
CY2022Q3	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions		usd
CY2022Q3	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	MEDS	Loss On Inventory Investments LossOnInventoryInvestments		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Increase Decrease In Deferred Fuel Costs IncreaseDecreaseInDeferredFuelCosts		usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities		usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments For Software PaymentsForSoftware		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Central Index Key EntityCentralIndexKey	0001382574
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39199
	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	261-0281
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MEDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9318708	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	321715	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3122578	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	850306	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978973	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	75950	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	56279	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	249785	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	216414	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	875250	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2373006	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	4374244	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68036	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98751	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1099002	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	60136	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1100186	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1233033	usd
CY2022Q3	us-gaap	Assets Assets	4689261	usd
CY2021Q4	us-gaap	Assets Assets	5766164	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	744412	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	477028	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	312077	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	270437	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	105926	usd
CY2022Q3	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	542143	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	190127	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178561	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	166667	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2061352	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	926026	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	937998	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069965	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	333333	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3332683	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1995991	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8398708	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8398708	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8166457	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8166457	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	83	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20193271	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20017528	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18794350	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16247437	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1399004	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3770173	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-42426	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4689261	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5766164	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2400311	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2550046	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8919312	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7501535	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	998320	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1269005	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5010704	usd
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39199
	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3995792	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1401991	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	1281041	usd
	us-gaap	Gross Profit GrossProfit	3908608	usd
	us-gaap	Gross Profit GrossProfit	3505743	usd
CY2021Q3	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1285	usd
	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1226426	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	937062	usd
CY2021Q3	us-gaap	Salaries And Wages SalariesAndWages	1015816	usd
	us-gaap	Salaries And Wages SalariesAndWages	3185144	usd
	us-gaap	Salaries And Wages SalariesAndWages	2878237	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	95275	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	205457	usd
	us-gaap	Professional Fees ProfessionalFees	307341	usd
	us-gaap	Professional Fees ProfessionalFees	757263	usd
CY2022Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	191611	usd
CY2021Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	98867	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	567690	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	462626	usd
CY2022Q3	MEDS	Technology Expense TechnologyExpense	298586	usd
CY2021Q3	MEDS	Technology Expense TechnologyExpense	338637	usd
	MEDS	Technology Expense TechnologyExpense	842433	usd
	MEDS	Technology Expense TechnologyExpense	678110	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	286488	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	917105	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1484709	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2013050	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1809022	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2577167	usd
	us-gaap	Operating Expenses OperatingExpenses	6387317	usd
	us-gaap	Operating Expenses OperatingExpenses	8015712	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-407031	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1296126	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2478709	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4509969	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8396	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8396	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4100	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	130107	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	5622	usd
	us-gaap	Interest Expense InterestExpense	140626	usd
	us-gaap	Interest Expense InterestExpense	21574	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121711	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5622	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-128130	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21574	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-59926	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-503003	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1301748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2546913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4531543	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-503003	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1301748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2546913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25739	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8249653	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8163522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8203202	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8126689	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32083	usd
CY2022Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32783	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-965836	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12222	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	16994	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63126	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	17661	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8679158	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	98247	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	75738	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-651519	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8201624	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100416	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1821	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61392	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2578276	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5786977	usd
	MEDS	Loss On Inventory Investments LossOnInventoryInvestments	1226426	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	41250	usd
CY2021Q3	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	15001	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	21640	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	54175	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4617295	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
	us-gaap	Depreciation Depreciation	11815	usd
	us-gaap	Depreciation Depreciation	5250	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	67439	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	191305	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	107430	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	239913	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-98841	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	616215	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21640	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4100	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	132847	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	97436	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29400	usd
	us-gaap	Increase Decrease In Deferred Fuel Costs IncreaseDecreaseInDeferredFuelCosts	78000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-227508	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	819988	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-198088	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	284499	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19671	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1162932	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	875250	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5140	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120401	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-96954	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	267384	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18391	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178714	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	96825	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	105926	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2755979	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2139511	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
	us-gaap	Payments For Software PaymentsForSoftware	335902	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-312902	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	225000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	282857	usd
	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest	792500	usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1821	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15001	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268018	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-208178	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2800863	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2347689	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5919578	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	321715	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3571889	usd
	us-gaap	Interest Paid Net InterestPaidNet	3328	usd
	us-gaap	Interest Paid Net InterestPaidNet	26321	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	98841	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	616215	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	26924	usd
CY2022Q3	MEDS	Number Of Options Outstanding NumberOfOptionsOutstanding	338857	shares
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-503003	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1301748	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2546913	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4531543	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8249653	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8163522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8203202	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8126689	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	MEDS	Initial Lease Liability InitialLeaseLiability	15000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	321715	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3122578	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	850306	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18800000	usd
CY2022Q3	MEDS	Working Capital WorkingCapital	300000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	300000	usd
CY2022Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29400	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	500000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	44535	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.32
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P0Y11M12D
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	208078	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3027	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	3.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14584	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.06
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	26924	shares
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.06
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P0Y9M
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	28809	usd
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber	26924	shares
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	0.06
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P0Y9M
CY2022Q3	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1	28809	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	67439	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	137130	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_801_eus-gaap--LossContingencyDisclosures_zCm2v8Zey5z2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_825_zt2wGrX9YGdg">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Studebaker Defense Group, LLC </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $<span id="xdx_906_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zSDNYL0ec7Yk" title="Down payment">500,000</span> and Studebaker would deliver <span id="xdx_909_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zDd71SDLt2Xf">180,000</span> boxes of nitrile gloves by August 14, 2020. Integra wired the $<span id="xdx_908_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zGKhpfA9Mhnh" title="Loss contingency, damages sought, value">500,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_90D_ecustom--LossOnInventoryInvestment_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zh1kuZuRk5ch" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $<span id="xdx_90B_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zynthC8XZSof" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_909_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zaFfOakUlEbe" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. Integra wired the $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zUUr7x0xKkLi">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $<span id="xdx_907_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_z5OaeTeB3wph">581,250</span> and Crecom acknowledged that Integra was entitled to a refund. As of February 2021, Crecom had not returned any funds and Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by Integra was stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for Integra. At June 30, 2021, the $<span id="xdx_90C_ecustom--LossOnInventoryInvestment_c20220101__20220930__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zJMLPNisf1ph" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GSG PPE, LLC</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zsEmEzR9ha7f" title="Debt instrument face amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_90A_ecustom--AttorneyFees_c20220101__20220930_zMA2SPxaJ33l" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed Integra $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--WaxmanMember_z4INglcnwiK7">630,000</span>. On September 30, 2021, the $<span id="xdx_90A_ecustom--BadDebtExpenses_c20210101__20210930_zopv4Kr8hrS9" title="Bad debt expense">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_900_ecustom--AttorneyFees_c20220101__20220630__srt--TitleOfIndividualAxis__custom--WaxmanMember_ze6j5oBxROvk" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. In June 2022, the Company received a $<span id="xdx_90B_ecustom--PaymentReceived_c20220101__20220930__dei--LegalEntityAxis__custom--GSGPPELLCMember_zCoeJaUzA5n" title="Payment received">100,000</span> payment from GSG and recorded a credit to Bad Debt Expense, future payments will also be recorded as a credit to the Bad Debt Expense less applicable interest and recovered legal fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jain, et al., v. Memantine, et al. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $<span id="xdx_90E_eus-gaap--LossContingencyDamagesPaidValue_c20210501__20210514_zcsATJHX4uuh" title="Compensatory amount value">425,000</span> in compensatory damages, treble damages, punitive damages, and fees and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20220201__20220228_zijNKsLM7rag" title="Settlement payment amount">225,000</span> was made. Because the complaint purports to be a derivative action, court approval was required, which approval was received on March 14, 2022. As a result of the settlement, the Plaintiff’s dismissed their lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
	MEDS	Attorney Fees AttorneyFees	630000	usd
	MEDS	Bad Debt Expenses BadDebtExpenses	630000	usd
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	425000	usd
CY2021Q3	us-gaap	Assets Assets	5514101	usd
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	225000	usd
CY2022Q3	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291537	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	300286	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	309294	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	318573	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	122912	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	63055	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1405657	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	291713	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1113944	usd
CY2022Q3	MEDS	Lease Obligation Current LeaseObligationCurrent	188558	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	925386	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	14181	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	132847	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	97436	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	120403	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	96954	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8919312	usd
	us-gaap	Gross Profit GrossProfit	3908608	usd
CY2022Q3	us-gaap	Assets Assets	4689261	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5010704	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7501535	usd
	us-gaap	Gross Profit GrossProfit	3505743	usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	261-0281
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	MEDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9318708	shares
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978973	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	75950	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	56279	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	249785	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	216414	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	875250	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2373006	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	4374244	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68036	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98751	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1099002	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49031	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	60136	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1100186	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1233033	usd
CY2022Q3	us-gaap	Assets Assets	4689261	usd
CY2021Q4	us-gaap	Assets Assets	5766164	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	744412	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	477028	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	312077	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	270437	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	105926	usd
CY2022Q3	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	542143	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	190127	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178561	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	166667	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2061352	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	926026	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	937998	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3995792	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1069965	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	333333	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3332683	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1995991	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8398708	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8398708	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8166457	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8166457	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	83	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20193271	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20017528	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18794350	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16247437	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1399004	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3770173	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-42426	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4689261	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5766164	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2400311	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2550046	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8919312	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7501535	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	998320	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1269005	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5010704	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3995792	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1401991	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	1281041	usd
	us-gaap	Gross Profit GrossProfit	3908608	usd
	us-gaap	Gross Profit GrossProfit	3505743	usd
CY2021Q3	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1285	usd
	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	1226426	usd
CY2022Q3	us-gaap	Salaries And Wages SalariesAndWages	937062	usd
CY2021Q3	us-gaap	Salaries And Wages SalariesAndWages	1015816	usd
	us-gaap	Salaries And Wages SalariesAndWages	3185144	usd
	us-gaap	Salaries And Wages SalariesAndWages	2878237	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	95275	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	205457	usd
	us-gaap	Professional Fees ProfessionalFees	307341	usd
	us-gaap	Professional Fees ProfessionalFees	757263	usd
CY2022Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	191611	usd
CY2021Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	98867	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	567690	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	462626	usd
CY2022Q3	MEDS	Technology Expense TechnologyExpense	298586	usd
CY2021Q3	MEDS	Technology Expense TechnologyExpense	338637	usd
	MEDS	Technology Expense TechnologyExpense	842433	usd
	MEDS	Technology Expense TechnologyExpense	678110	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	286488	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	917105	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1484709	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2013050	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1809022	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	2577167	usd
	us-gaap	Operating Expenses OperatingExpenses	6387317	usd
	us-gaap	Operating Expenses OperatingExpenses	8015712	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-407031	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1296126	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2478709	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4509969	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8396	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8396	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4100	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	130107	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	5622	usd
	us-gaap	Interest Expense InterestExpense	140626	usd
	us-gaap	Interest Expense InterestExpense	21574	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121711	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5622	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-128130	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21574	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-503003	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1301748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2546913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25739	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-59926	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-503003	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1301748	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2546913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4531543	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8249653	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8163522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8203202	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8126689	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022Q1	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	32083	usd
CY2022Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	32783	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-965836	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2887578	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	12222	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	16994	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1112261	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63126	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	17661	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1356578	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8679158	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	98247	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	75738	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-651519	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8201624	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100416	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1821	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61392	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-2578276	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5786977	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	41250	usd
CY2021Q3	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	15001	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	21640	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	4100	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	54175	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4617295	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
	us-gaap	Depreciation Depreciation	11815	usd
	us-gaap	Depreciation Depreciation	5250	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	67439	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	191305	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	107430	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	239913	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-98841	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	616215	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21640	usd
	MEDS	Loss On Inventory Investments LossOnInventoryInvestments	1226426	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	132847	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	97436	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29400	usd
	us-gaap	Increase Decrease In Deferred Fuel Costs IncreaseDecreaseInDeferredFuelCosts	78000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-227508	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	819988	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-198088	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	284499	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19671	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1162932	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	875250	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5140	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-120401	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-96954	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	267384	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18391	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178714	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	96825	usd
	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	105926	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2755979	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2139511	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	usd
	us-gaap	Payments For Software PaymentsForSoftware	335902	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-312902	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	225000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	282857	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	275000	usd
	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1821	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15001	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	98841	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	616215	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268018	usd
CY2022Q1	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	225000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	26924	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-208178	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2800863	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2347689	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5919578	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	321715	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3571889	usd
	us-gaap	Interest Paid Net InterestPaidNet	3328	usd
	us-gaap	Interest Paid Net InterestPaidNet	26321	usd
	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
	us-gaap	Notes Issued1 NotesIssued1	500000	usd
	MEDS	Intangible Asset Contribution From Non Controlling Interest IntangibleAssetContributionFromNonControllingInterest	792500	usd
CY2022Q3	MEDS	Number Of Options Outstanding NumberOfOptionsOutstanding	338857	shares
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-528742	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1301748	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-503003	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1301748	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2546913	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4531543	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8249653	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8163522	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8203202	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8126689	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	usd
	MEDS	Bad Debt Expenses BadDebtExpenses	630000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18800000	usd
CY2022Q3	MEDS	Working Capital WorkingCapital	300000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	300000	usd
CY2022Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	29400	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	500000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	44535	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.32
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P0Y11M12D
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	208078	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3027	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	3.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14584	shares
	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.06
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	26924	shares
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.06
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P0Y9M
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	28809	usd
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber	26924	shares
CY2022Q3	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	0.06
	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P0Y9M
CY2022Q3	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1	28809	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	67439	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	137130	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_801_eus-gaap--LossContingencyDisclosures_zCm2v8Zey5z2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_825_zt2wGrX9YGdg">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Studebaker Defense Group, LLC </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $<span id="xdx_906_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zSDNYL0ec7Yk" title="Down payment">500,000</span> and Studebaker would deliver <span id="xdx_909_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zDd71SDLt2Xf">180,000</span> boxes of nitrile gloves by August 14, 2020. Integra wired the $<span id="xdx_908_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zGKhpfA9Mhnh" title="Loss contingency, damages sought, value">500,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $<span id="xdx_90D_ecustom--LossOnInventoryInvestment_c20220101__20220630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zh1kuZuRk5ch" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $<span id="xdx_90B_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zynthC8XZSof" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_909_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zaFfOakUlEbe" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. Integra wired the $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_zUUr7x0xKkLi">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $<span id="xdx_907_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IntegraMember_z5OaeTeB3wph">581,250</span> and Crecom acknowledged that Integra was entitled to a refund. As of February 2021, Crecom had not returned any funds and Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by Integra was stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for Integra. At June 30, 2021, the $<span id="xdx_90C_ecustom--LossOnInventoryInvestment_c20220101__20220930__dei--LegalEntityAxis__custom--IntegraMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zJMLPNisf1ph" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GSG PPE, LLC</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zsEmEzR9ha7f" title="Debt instrument face amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_90A_ecustom--AttorneyFees_c20220101__20220930_zMA2SPxaJ33l" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed Integra $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--TitleOfIndividualAxis__custom--WaxmanMember_z4INglcnwiK7">630,000</span>. On September 30, 2021, the $<span id="xdx_90A_ecustom--BadDebtExpenses_c20210101__20210930_zopv4Kr8hrS9" title="Bad debt expense">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_900_ecustom--AttorneyFees_c20220101__20220630__srt--TitleOfIndividualAxis__custom--WaxmanMember_ze6j5oBxROvk" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. In June 2022, the Company received a $<span id="xdx_90B_ecustom--PaymentReceived_c20220101__20220930__dei--LegalEntityAxis__custom--GSGPPELLCMember_zCoeJaUzA5n" title="Payment received">100,000</span> payment from GSG and recorded a credit to Bad Debt Expense, future payments will also be recorded as a credit to the Bad Debt Expense less applicable interest and recovered legal fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jain, et al., v. Memantine, et al. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $<span id="xdx_90E_eus-gaap--LossContingencyDamagesPaidValue_c20210501__20210514_zcsATJHX4uuh" title="Compensatory amount value">425,000</span> in compensatory damages, treble damages, punitive damages, and fees and costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20220201__20220228_zijNKsLM7rag" title="Settlement payment amount">225,000</span> was made. Because the complaint purports to be a derivative action, court approval was required, which approval was received on March 14, 2022. As a result of the settlement, the Plaintiff’s dismissed their lawsuit with prejudice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	425000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3995792	usd
CY2022Q3	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2022Q3	MEDS	Initial Lease Liability InitialLeaseLiability	15000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	291537	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	300286	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	309294	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	318573	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	122912	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	63055	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1405657	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	291713	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1113944	usd
CY2022Q3	MEDS	Lease Obligation Current LeaseObligationCurrent	188558	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	925386	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	14181	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	132847	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	97436	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	120403	usd
	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	96954	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8919312	usd
	us-gaap	Gross Profit GrossProfit	3908608	usd
CY2022Q3	us-gaap	Assets Assets	4689261	usd
	us-gaap	Profit Loss ProfitLoss	-2606839	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5010704	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7501535	usd
	us-gaap	Gross Profit GrossProfit	3505743	usd
CY2021Q3	us-gaap	Assets Assets	5514101	usd
	us-gaap	Profit Loss ProfitLoss	-4531543	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1804533	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-22-030832-index-headers.html	Edgar Link	pending
0001493152-22-030832-index.html	Edgar Link	pending
0001493152-22-030832.txt	Edgar Link	pending
0001493152-22-030832-xbrl.zip	Edgar Link	pending
ex10-10.htm	Edgar Link	pending
ex10-10_001.jpg	Edgar Link	pending
ex10-10_002.jpg	Edgar Link	pending
ex10-10_003.jpg	Edgar Link	pending
ex10-10_004.jpg	Edgar Link	pending
ex10-10_005.jpg	Edgar Link	pending
ex10-10_006.jpg	Edgar Link	pending
ex10-10_007.jpg	Edgar Link	pending
ex10-10_008.jpg	Edgar Link	pending
ex10-10_009.jpg	Edgar Link	pending
ex10-10_010.jpg	Edgar Link	pending
ex10-10_011.jpg	Edgar Link	pending
ex10-10_012.jpg	Edgar Link	pending
ex10-10_013.jpg	Edgar Link	pending
ex10-10_017.jpg	Edgar Link	pending
ex10-10_018.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
form10-q_002.jpg	Edgar Link	pending
form10-q_003.jpg	Edgar Link	pending
meds-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
meds-20220930_cal.xml	Edgar Link	unprocessable
meds-20220930_def.xml	Edgar Link	unprocessable
meds-20220930_pre.xml	Edgar Link	unprocessable
meds-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2022 Q4 Form 10-Q Financial Statement

#000149315222030832 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2022 Q4 Form 10-Q Financial Statement

#000149315222030832 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx